HYPMET | Hyperpolarized Magnetic Resonance at the point-of-care

Summary
HYPMET proposes a pioneering research methodology for hyperpolarized magnetic resonance for real-time monitoring of upregulated metabolic pathways in cancer cells and in-vivo and for body fluid metabolic analyses with the prospect of revolutionizing the medical approach to personalised treatments.
A common analytical method for structural biology, medical imaging, and chemical analysis is nuclear magnetic resonance (NMR), which is flexible but intrinsically insensitive. Even in the most sensitive NMR spectra, many endogenous compounds found in blood, saliva, or urine are currently unresolved.
HYPMET will establish a ground-breaking technology enabling the detection of body fluids metabolites below the current limit of NMR detection (~μM) and the real-time monitoring of clinically relevant metabolic pathways in-cells and in-vivo; it will enable NMR metabolomics analyses at the point-of-care and will be fully compatible with personalised medical treatments; it will be compact (less than 10×10×30 cm) and will not require superconducting magnets.
Emerging methods (e.g. hyperpolarisation methods - HM) can boost the NMR signal intensity. HYPMET will merge two HMs to achieve NMR signal enhancements of several thousand-fold continuously, in the liquid state and at ultra-low-magnetic field (ULF, i.e.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101117082
Start date: 01-05-2024
End date: 30-04-2029
Total budget - Public funding: 1 499 968,75 Euro - 1 499 968,00 Euro
Cordis data

Original description

HYPMET proposes a pioneering research methodology for hyperpolarized magnetic resonance for real-time monitoring of upregulated metabolic pathways in cancer cells and in-vivo and for body fluid metabolic analyses with the prospect of revolutionizing the medical approach to personalised treatments.
A common analytical method for structural biology, medical imaging, and chemical analysis is nuclear magnetic resonance (NMR), which is flexible but intrinsically insensitive. Even in the most sensitive NMR spectra, many endogenous compounds found in blood, saliva, or urine are currently unresolved.
HYPMET will establish a ground-breaking technology enabling the detection of body fluids metabolites below the current limit of NMR detection (~μM) and the real-time monitoring of clinically relevant metabolic pathways in-cells and in-vivo; it will enable NMR metabolomics analyses at the point-of-care and will be fully compatible with personalised medical treatments; it will be compact (less than 10×10×30 cm) and will not require superconducting magnets.
Emerging methods (e.g. hyperpolarisation methods - HM) can boost the NMR signal intensity. HYPMET will merge two HMs to achieve NMR signal enhancements of several thousand-fold continuously, in the liquid state and at ultra-low-magnetic field (ULF, i.e.

Status

SIGNED

Call topic

ERC-2023-STG

Update Date

12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.1 Excellent Science
HORIZON.1.1 European Research Council (ERC)
HORIZON.1.1.0 Cross-cutting call topics
ERC-2023-STG ERC STARTING GRANTS
HORIZON.1.1.1 Frontier science
ERC-2023-STG ERC STARTING GRANTS